AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29098841
Drug: Methotrexate tablets
RxNorm normalized name: Methotrexate Tablets
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablets (chemical medicine group)
Trial: 10708052
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (zidovudine + lamivudine + ritonavir)
Trial: 10708052
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (zidovudine + lamivudine)
Trial: 8403956
Drug: Continuous nebulization
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulization of albuterol (0.3 mg/kg/hr)
Trial: 8403956
Drug: Intermittent nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulization of albuterol (0.3 mg/kg over 20 mins every hour)
Trial: 8403956
Drug: Continuous nebulization
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulization of albuterol
Trial: 8403956
Drug: Intermittent nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulization of albuterol
Trial: 3511936
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily theophylline
Trial: 9040452
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg)
Trial: 30231787
Drug: Oral fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluids 6 hours postoperatively
Trial: 28375647
Drug: Once-daily triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.5 μg/25 μg; ELLIPTA inhaler)
Trial: 19590476
Drug: G-ER 1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-ER 1800 mg once-daily administered in the evening
Trial: 19590476
Drug: G-ER 1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM)
Trial: 19590476
Drug: Placebo G-ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo G-ER
Trial: 31162017
Drug: Doxycycline 200
RxNorm normalized name: doxycycline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 200 mg/day for 6 weeks
Trial: 11071065
Drug: Fluvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin treatment for 16 weeks
Trial: 9052620
Drug: 5‐fluorouracil (5‐FU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (5‐FU) group: five subconjunctival injections of 5 mg 5‐FU, starting from day 8 after surgery, one injection per week.
Trial: 9052620
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: no injections.
Trial: 8448099
Drug: 18-gauge Tuohy-Schliff
RxNorm normalized name: Schiff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18-gauge Tuohy-Schliff needle/20-gauge catheter combination (group 1)
Trial: 8448099
Drug: 20-gauge Quincke
RxNorm normalized name: QUINCE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-gauge Quincke point needle/24-gauge catheter combination (group 2)
Trial: 3512898
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy with biological feedback (BFB) (group 2)
Trial: 30940872
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose protocols with 400 µm voxel size and 7.4 mAs
Trial: 23930843
Drug: HFM-AB1 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFM-AB1 (500 ml antioxidant beverage 1; apple, grape, blueberry and pomegranate juices and grape skin, grape seed and green tea extracts)
Trial: 23930843
Drug: HFM-AB2 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFM-AB2 (500 ml antioxidant beverage 2; pineapple, black currant and plum juices)
Trial: 23930843
Drug: HFM-PB (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFM-PB (500 ml placebo beverage, free from fruit)
Trial: 19581564
Drug: Moderate-dosage bilateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-dosage bilateral ECT
Trial: 15037554
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide synthase inhibitor (L-NMMA)
Trial: 8848192
Drug: Selective anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective anesthesia of the right hemisphere during right intracarotid barbiturate infusion
Trial: 25494658
Drug: Essential oil
RxNorm normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential oil (EO) mouthrinse (40 mL/day for 90 days)
Trial: 25494658
Drug: Placebo mouthrinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthrinse (40 mL/day for 90 days)
Trial: 24070431
Drug: DPV 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPV 0.05% gel
Trial: 18080351
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo gel
Trial: 17241844
Drug: Universal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal placebo gel
Trial: 17632215
Drug: Olanzapine (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5-20 mg/d)
Trial: 12442883
Drug: Amisulpride (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amisulpride (200-800 mg/d)
Trial: 9744776
Drug: Low-dose carboplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carboplatin (CG-Calvert formula)
Trial: 4043678
Drug: Clonidine 0.3
RxNorm normalized name: CLONIDINE 0.3MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.3 mg
Trial: 31538430
Drug: Very short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Very short-term exposure to PM10 exceeding 100 µg/m3 for 2 hours
Trial: 28558817
Drug: Aerobic exercise,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic exercise, strength training, and physical therapy (3 months, biweekly 90-min sessions)
Trial: 28558817
Drug: Aerobic exercise,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic exercise, strength training, and physical therapy
Trial: 22086108
Drug: Intravaginal micronized
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal micronized natural progesterone (200 mg daily)
Trial: 17126073
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg daily)
Trial: 19571282
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg daily)
Trial: 10930686
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Russian live attenuated and US inactivated trivalent influenza vaccines
Trial: 10930686
Drug: Live vaccine
RxNorm normalized name: rubella virus live vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live vaccine alone
Trial: 9778752
Drug: Inactivated vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated vaccine alone
Trial: 10930686
Drug: Live vaccine
RxNorm normalized name: rubella virus live vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live vaccine (alone or in combination with inactivated vaccine)
Trial: 10930686
Drug: Combination vaccines
RxNorm normalized name: Hepatitis vaccine combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vaccines
Trial: 9031444
Drug: Dalteparin (Fragmin)
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (Fragmin) 5000 i.u. once daily for 4 weeks
Trial: 8081065
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D3 supplements (1.2 g calcium and 800 IU vitamin D3 daily)
Trial: 26765317
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation treatment (ADT)
Trial: 7037048
Drug: Ephedrine (0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (0.50 mg/kg)
Trial: 7037048
Drug: Ephedrine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (0.25 mg/kg)
Trial: 26170627
Drug: Lesinurad (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad (tablets or capsules)
Trial: 9821420
Drug: 5-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-day regimen of amoxicillin/clavulanate in 3 divided doses
Trial: 9821420
Drug: 10-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-day regimen of amoxicillin/clavulanate in 3 divided doses
Trial: 2195978
Drug: Labetalol (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (1, 2, then 3 tablets/day, adjusted according to BP)
Trial: 2195978
Drug: Nifedipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (2 tablets/day, recommended dosage)
Trial: 31983158
Drug: 10-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day course of triple therapy (Rabeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg twice daily for 10 days plus 4 days placebo)
Trial: 19132203
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg and Simvastatin 10 mg daily (E10/S10; n = 16)
Trial: 15562917
Drug: Low-dose doxycycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose doxycycline (20 mg, b.i.d.) for 3 months plus scaling and root planing (SRP)
Trial: 11686749
Drug: Solution-focused brief
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution-focused brief therapy (SFBT) training
Trial: 9159625
Drug: Low-intensity oral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity oral anticoagulants (INR 2.5 to 3.5) plus aspirin (100 mg/day)
Trial: 9159625
Drug: High-intensity oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity oral anticoagulants (INR 3.5 to 4.5)
Trial: 29430839
Drug: Carnosine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine supplementation (500 mg per day for 2 months)
Trial: 29430839
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg per day for 2 months)
Trial: 23161302
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alpha‐2a (180 μg weekly)
Trial: 14693624
Drug: Ambulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulation with epidural analgesia (0.08% bupivacaine‐epinephrine plus 1 microg/mL of sufentanil)
Trial: 2556727
Drug: Intravenous alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alprazolam
Trial: 5134998
Drug: Dimethyltriazeno imidazole
RxNorm normalized name: 4-(dimethyltriazeno)imidazole-5-carboxamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethyltriazeno imidazole carboxamide, 2.0 mg/kg for 10 days
Trial: 5134998
Drug: Dimethyltriazeno imidazole
RxNorm normalized name: 4-(dimethyltriazeno)imidazole-5-carboxamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethyltriazeno imidazole carboxamide, 4.5 mg/kg for 10 days
Trial: 31785626
Drug: Cervical artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervical artificial insemination (CAI; 3 × 10^9 spermatozoa/90 mL)
Trial: 25118962
Drug: Bushen Fangchuan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bushen Fangchuan (BF) tablet
Trial: 22238571
Drug: Increased cerebro-cerebral
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased cerebro-cerebral coherence between contralateral M1 and SMA during movement preparation and execution in GTS patients
Trial: 17522246
Drug: BSC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSC plus panitumumab, 6 mg/kg i.v., every other week
Trial: 837962
Drug: Doxantrazole 200
RxNorm normalized name: Contrazole
DrugBank: Zoxazolamine (DB19372)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxantrazole 200 mg taken orally 1 hour before exercise test
Trial: 837962
Drug: Doxantrazole 400
RxNorm normalized name: Contrazole
DrugBank: Zoxazolamine (DB19372)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxantrazole 400 mg taken orally
Trial: 31805571
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin (TAM) + Serenoa repens (SR) 320 mg/day + Bovine Colostrum (BC) 30 mg/day
Trial: 31060549
Drug: Standardized aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 250 mg twice daily
Trial: 31060549
Drug: Standardized aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized aqueous extract of Phyllanthus emblica (P. emblica) 500 mg twice daily
Trial: 25769436
Drug: Natural cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural cocoa consumption (12.7 g natural cocoa, 148 kcal/serving) for 4 weeks
Trial: 28893866
Drug: FK506 (tacrolimus)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FK506 (tacrolimus) therapy with target levels <2, 2-3, and 3-5 ng·mL-1
Trial: 28893866
Drug: FK506 (tacrolimus)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FK506 (tacrolimus) therapy
Trial: 19920417
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (150 mg)
Trial: 19920417
Drug: Levobupivacaine 0.33%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.33% (99 mg)
Trial: 29170486
Drug: Small-particle size
RxNorm normalized name: Smallpox (Vaccinia) Vaccine, Live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-particle size emulsion (SPE) - diameter 0.290 μm, 10 g lipid emulsion, 190 g yoghurt
Trial: 29170486
Drug: Control non-emulsion
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control non-emulsion (NE) - 10 g non-emulsion lipid, 190 g yoghurt
Trial: 26267219
Drug: Active treatments
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatments (Rupatadine and Desloratadine)
Trial: 18166407
Drug: Dorzolamide/timolol fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide/timolol fixed combination (DTFC) twice daily for 6 months
Trial: 11167307
Drug: Oral creatine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral creatine supplementation (20 g d(‐1) for 7 days)
Trial: 16492856
Drug: succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: succinylcholine 1.0 mg/kg
Trial: 31537420
Drug: rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rocuronium 0.6 mg/kg
Trial: 6472796
Drug: Cysteine Eye-Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine Eye-Gel
Trial: 27383495
Drug: Linkus syrup
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linkus syrup
Trial: 31274602
Drug: Acetaminophen 15
RxNorm normalized name: acetaminophen 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 15 mg/kg
Trial: 22572984
Drug: Preseasonal immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preseasonal immunotherapy with olive pollen allergoid
Trial: 10397375
Drug: Comparator drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator drugs
Trial: 10594475
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg three times daily for 4 consecutive days)
Trial: 7795940
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of physical practice and rest periods (two sessions)
Trial: 30838890
Drug: 12-h intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-h intravenous acetylcysteine regimen (200 mg/kg over 4 h, 50 mg/kg over 8 h)
Trial: 30838890
Drug: 20-h intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-h intravenous acetylcysteine regimen (200 mg/kg over 4 h, 100 mg/kg over 16 h)
Trial: 25401417
Drug: Liberal erythrocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal erythrocyte transfusion strategy (transfusion when hemoglobin <9 g/dl)
Trial: 25401417
Drug: Restrictive erythrocyte
RxNorm normalized name: erythrocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive erythrocyte transfusion strategy (transfusion when hemoglobin <7 g/dl)
Trial: 9075649
Drug: Interferon-alpha therapy
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha therapy
Trial: 14649969
Drug: Ginger (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (500 mg orally three times daily for three days)
Trial: 14649969
Drug: Vitamin B6
RxNorm normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B6 (10 mg orally three times daily for three days)
Trial: 10220013
Drug: G to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G to A polymorphism at position -1438 of the 5-HT2A receptor gene
Trial: 1369707
Drug: Nicardipine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine treatment
Trial: 6999546
Drug: PGE2-gel (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2-gel (0.25 mg)
Trial: 377896
Drug: PGE2-gel (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGE2-gel (0.25 mg) with nifedipine
Trial: 19884997
Drug: Single Interscalene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Interscalene Block combined with Continuous Intra-bursal Infusion of Ropivacaine (ISB-IB)
Trial: 15114199
Drug: Salbutamol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (3 x 2 puffs, 0.2 mg)
Trial: 15114199
Drug: Salbutamol combined
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol combined with methylprednisolone (40 mg/day orally)
Trial: 9737124
Drug: Ramipril (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (1.25 mg/d, n = 16)
Trial: 26138866
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg moxifloxacin (positive control)
Trial: 30652317
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (IG) - skin care programme with cream dispensers and electronic monitoring.
Trial: 23601071
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day vitamin E and 150 mg/day vitamin C
Trial: 12207146
Drug: Cortisol (hydrocortisone)
RxNorm normalized name: Corticool
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cortisol (hydrocortisone) 20 mg
Trial: 12207146
Drug: Cortisol (hydrocortisone)
RxNorm normalized name: Corticool
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cortisol (hydrocortisone) 40 mg
Trial: 23343596
Drug: d-amphetamine (AMPH)
RxNorm normalized name: amphetamine / dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (AMPH) 0 mg (placebo)
Trial: 19672133
Drug: Adherence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence therapy (during the 12 months after enrollment)
Trial: 17088333
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (Dysport) injection (500 Speywood units)
Trial: 11591194
Drug: Repeated low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Repeated low-dose allergen exposure (1/5 of the provocative dose)
Trial: 2655907
Drug: Fenofibrate 100
RxNorm normalized name: fenofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 100 mg three times daily for eight weeks
Trial: 2655907
Drug: Fenofibrate 100
RxNorm normalized name: fenofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 100 mg three times daily for eight weeks (Group B)
Trial: 26282643
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg per day
Trial: 22036019
Drug: Aspirin placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin placebo
Trial: 26282643
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch 30 g per day